Eli Lilly sets 2024 revenue at $45bn amid revised guidance
Eli Lilly and Company, a leading global pharmaceutical firm, has adjusted its 2024 revenue forecast to $45 billion, marking a 32% increase from the previous ... Read More
FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer's treatment developed by Eli Lilly and Company (NYSE: LLY). This treatment, specifically ... Read More